AU2001253612A1 - Daily treatment for erectile dysfunction using a pde5 inhibitor - Google Patents

Daily treatment for erectile dysfunction using a pde5 inhibitor

Info

Publication number
AU2001253612A1
AU2001253612A1 AU2001253612A AU5361201A AU2001253612A1 AU 2001253612 A1 AU2001253612 A1 AU 2001253612A1 AU 2001253612 A AU2001253612 A AU 2001253612A AU 5361201 A AU5361201 A AU 5361201A AU 2001253612 A1 AU2001253612 A1 AU 2001253612A1
Authority
AU
Australia
Prior art keywords
pde5 inhibitor
pde5
methyl
chronic
article
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253612A
Other languages
English (en)
Inventor
Inigo Saenz De Tejada
Kenneth M. Ferguson
John S. Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Icos LLC
Original Assignee
Lilly Icos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC
Publication of AU2001253612A1 publication Critical patent/AU2001253612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2001253612A 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pde5 inhibitor Abandoned AU2001253612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09558911 2000-04-26
US09/558,911 US6451807B1 (en) 1999-04-30 2000-04-26 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
PCT/US2001/012512 WO2001080860A2 (en) 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pde5 inhibitor

Publications (1)

Publication Number Publication Date
AU2001253612A1 true AU2001253612A1 (en) 2001-11-07

Family

ID=24231497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253612A Abandoned AU2001253612A1 (en) 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pde5 inhibitor

Country Status (20)

Country Link
US (2) US6451807B1 (cs)
EP (1) EP1276481A2 (cs)
JP (1) JP2003531174A (cs)
KR (1) KR20030007551A (cs)
CN (1) CN1446091A (cs)
AU (1) AU2001253612A1 (cs)
BR (1) BR0110373A (cs)
CA (1) CA2407519A1 (cs)
CZ (1) CZ20023577A3 (cs)
EA (1) EA200201011A1 (cs)
HR (1) HRP20020827A2 (cs)
HU (1) HUP0300477A3 (cs)
IL (1) IL152227A0 (cs)
MX (1) MXPA02010539A (cs)
NO (1) NO20025138L (cs)
NZ (1) NZ521869A (cs)
PL (1) PL360186A1 (cs)
SK (1) SK15392002A3 (cs)
WO (1) WO2001080860A2 (cs)
ZA (1) ZA200208776B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
NO20002097L (no) * 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
JP2010501577A (ja) * 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
TWI462923B (zh) * 2010-10-18 2014-12-01 Univ Kaohsiung Medical Ｋｍｕｐ－３之心肌梗塞疾患用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP6578046B1 (ja) * 2018-08-23 2019-09-18 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 Ｐｄｅ５阻害用医薬組成物及びｐｄｅ５阻害用食品組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931445A (en) 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CA2698716A1 (en) 1993-05-27 1994-12-08 The Board Of Regents Of The University Of Washington Cyclic gmp-binding, cyclic gmp-specific phosphodiesterase materials and methods
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
JP2002524564A (ja) 1998-09-16 2002-08-06 アイコス コーポレイション ｃＧＭＰホスホジエステラーゼ阻害剤としてのカルボリン誘導体

Also Published As

Publication number Publication date
JP2003531174A (ja) 2003-10-21
NZ521869A (en) 2004-10-29
HUP0300477A3 (en) 2004-10-28
US20030100478A1 (en) 2003-05-29
EP1276481A2 (en) 2003-01-22
US6451807B1 (en) 2002-09-17
ZA200208776B (en) 2003-06-03
CA2407519A1 (en) 2001-11-01
WO2001080860A3 (en) 2002-06-06
HRP20020827A2 (en) 2004-12-31
BR0110373A (pt) 2003-02-18
KR20030007551A (ko) 2003-01-23
NO20025138L (no) 2002-12-16
CN1446091A (zh) 2003-10-01
CZ20023577A3 (cs) 2003-06-18
IL152227A0 (en) 2003-05-29
PL360186A1 (en) 2004-09-06
SK15392002A3 (sk) 2003-03-04
WO2001080860A2 (en) 2001-11-01
NO20025138D0 (no) 2002-10-25
EA200201011A1 (ru) 2003-06-26
HUP0300477A2 (hu) 2003-06-28
MXPA02010539A (es) 2003-05-14

Similar Documents

Publication Publication Date Title
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
DK1173181T6 (en) COMPOSITION COMPREHENSIVE INHIBITORS FOR PHOSPHODIESTERASE TO treating sexual dysfunction
AU2001253612A1 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
US20010053780A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
CZ20001536A3 (cs) Orální léčivo